Search the Newsreel

Alto Neuroscience (ANRO) boosts cash to $243.7M as R&D spend surges

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, widening from the previous year, primarily due to increased R&D expenses which surged to $22.1 million. Despite the loss, the company significantly strengthened its balance sheet, increasing cash and cash equivalents …

EuroDry (NASDAQ:EDRY) Director Sells 500 Shares

EuroDry Director Aristeidis Pittas sold 500 shares of the company's stock for $18,900, reducing his holdings by 0.65%. This sale occurred shortly after EuroDry announced strong quarterly EPS of $2.44, significantly beating estimates, though revenue slightly missed expectations. The stock is trading near its …

EuroSports Global Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Minerva Neurosciences (NERV) elevates Anthony Aliquo to chief accounting officer role

Minerva Neurosciences (NERV) has promoted Anthony Aliquo to Chief Accounting Officer and principal accounting officer, effective August 10, 2026. This move includes an increase in his annual base salary to $296,696 and a performance bonus target of 35%. Frederick Ahlholm remains the Chief Financial …

NeuroPace Q2 Earnings Call Highlights

NeuroPace reported strong Q2 revenue growth driven by its RNS System for adult focal epilepsy, leading to a raised full-year revenue and adjusted EBITDA outlook. The company is also engaging with the FDA regarding expanding the RNS System's indication to idiopathic generalized epilepsy (IGE), …

Why Neurocrine Biosciences (NBIX) Stock Is Down Today

Neurocrine Biosciences (NBIX) stock is down 3.1% today, likely due to investor profit-taking and a reset of expectations following its late-July earnings release. While the company reported strong revenue growth and increased INGREZZA sales guidance, it also raised spending outlooks and highlighted the balance-sheet …

EuroDry (EDRY) corporate secretary sells 400 shares and holds 850 after trade

EuroDry Ltd.'s Corporate Secretary, Stefania Karmiri, reported the sale of 400 shares of common stock on August 11, 2026, at $38.50 per share. Following this transaction, she directly holds 850 shares of the company's common stock. The transaction was classified as an open market …

EuroHoldings Q2 net profit rises 423% to $4.3 million

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Neurocrine Biosciences stock experienced a dip after reports emerged of deaths and severe complications potentially linked to its drug Vykat XR, used for Prader-Willi syndrome. The FDA's adverse event data revealed seven deaths and over 100 serious events, primarily involving edema, respiratory, and cardiac …

Stoneweg Europe Stapled Trust refreshes board to bolster governance and succession

Euronet Worldwide (EEFT): Bank of Montreal group discloses 5.81% ownership stake

Bank of Montreal and its related entities have disclosed a passive ownership stake of 5.81% in Euronet Worldwide, Inc. (EEFT) common stock, totaling 2,214,718 shares. This information comes from a SCHEDULE 13G SEC filing, indicating that Bank of Montreal holds sole voting power over …

PRMB or CCEP: Which Is the Better Value Stock Right Now?

Investors with an interest in Beverages - Soft drinks stocks have likely encountered both Primo Brands (PRMB) and Coca-Cola European (CCEP). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. We …

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace (NPCE) reported strong second-quarter 2026 results, with earnings and revenues surpassing Zacks Consensus Estimates, driven by significant growth in its RNS System. The company also raised its full-year 2026 revenue guidance and improved its adjusted EBITDA loss outlook. NeuroPace highlighted advancements in AI-based …

Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug

Reports have emerged of seven deaths and 100 serious adverse events potentially linked to Neurocrine Biosciences’ Prader-Willi syndrome drug, Vykat, prompting concerns among clinicians and patient advocacy groups. Concurrently, Aardvark Therapeutics terminated its Phase 3 trial for ARD-101 for the same condition due to …

Earnings To Watch: XBP Global Holdings Inc (XBP) Reports Q2 2026 Result

XBP Global Holdings Inc (NASDAQ:XBP) is slated to release its Q2 2026 earnings on August 13, 2026, with analysts forecasting a revenue of $197.70 million and an earnings per share of -$1.04. Despite upward revisions in revenue estimates for 2026 and 2027, earnings estimates …

Prader-Willi experts flag safety risks linked to Neurocrine's rare disease drug

Experts in Prader-Willi Syndrome have raised safety concerns regarding Neurocrine's drug Vykat XR, citing serious adverse events reported in patients. Post-marketing surveillance revealed reports of edema, respiratory and cardiac complications, and seven deaths linked to the drug as of July 31st, though no causal …

EuroHoldings Ltd Reports Results for the Quarter and Six-Month Period, Ended June 30, 2026

EuroHoldings declares $0.14 dividend payable around Sept. 16

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

Neurocrine Biosciences announced the publication of KINECT-PRO™ Phase 4 study results, showing that INGREZZA® (valbenazine) capsules significantly improved patient-reported quality of life and daily functioning, alongside clinician-rated tardive dyskinesia (TD) movement severity. These improvements were seen across various patient demographics, including those with mild …

HC Wainwright Issues Pessimistic Forecast for Neurogene (NASDAQ:NGNE) Stock Price

Keurig Dr Pepper appoints Aaron Alt to board of directors and audit committee

Keurig Dr Pepper Inc. (NASDAQ:KDP) has announced the appointment of Aaron Alt as an independent member of its board of directors, effective August 14, 2026, increasing the board's size to ten. Mr. Alt will also join the board’s Audit and Finance Committee. This appointment …

Aaron Alt appointed to Keurig Dr Pepper board, joins Audit and Finance Committee

Keurig Dr Pepper has appointed Aaron Alt as an independent director, effective August 14, 2026. He will also serve as a member of the Audit and Finance Committee. This appointment was disclosed in an SEC filing by Keurig Dr Pepper Inc. [KDP] on August …

Keurig Dr Pepper Announces Appointment of New Director to its Board

Keurig Dr Pepper Inc. (NASDAQ: KDP) has announced the appointment of Aaron Alt to its Board of Directors, effective August 14, 2026. Alt, currently CFO of Cardinal Health, brings extensive experience in finance, capital allocation, and business transformation, and will serve on KDP's Audit …

Neurocrine slips on safety issues linked to Vykat XR (NBIX:NASDAQ)

Neurocrine Biosciences' shares fell following resurfacing safety concerns related to Vykat XR, a rare disease therapy acquired through Soleno Therapeutics. Reports of potential fatalities and severe side effects, such as edema, have been linked to the drug, though a definitive causal link has not …

REG - Coca-Cola EP PLC - Director/PDMR Shareholding

This article reports a Director/PDMR Shareholding notification for Coca-Cola Europacific Partners plc (CCEP). Juan de Rueda Gamboa, Chief Public Affairs, Communications and Sustainability Officer, received a grant of 9,172 Performance Share Units (PSUs) on August 12, 2026. These PSUs are granted under the Company's …

Eureka Forbes Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Euronet Worldwide, Inc. $EEFT Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP reduced its stake in Euronet Worldwide (NASDAQ:EEFT) by 11.3% in the second quarter, selling 58,832 shares but retaining a significant holding valued at $33.7 million. Despite this, other institutional investors increased their positions, and Director Thomas A. McDonnell purchased additional shares, …

HC Wainwright Has Bearish Estimate for NERV Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS estimate for Minerva Neurosciences (NASDAQ:NERV) to a loss of $0.14 per share, a significant reduction from its previous forecast of a $0.01 loss. The firm also projects a $0.50-per-share loss for the full fiscal year 2026, …

Eureka Forbes Q1 Results: Profit Jumps 46% On One-Time Gain, Revenue Up 15%

Neurocrine Biosciences rare disease drug possibly tied to safety issues, experts say

A group of physicians and experts in Prader-Willi syndrome has notified clinicians about a series of patient deaths and severe side effects potentially linked to Neurocrine Biosciences' newly approved drug, Vykat XR. Approved in March 2025, Vykat XR is intended to manage intense hunger …

Alto Neuroscience Reports Q2 Loss As ALTO-207 Program Expands

Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, an increase from $17.7 million a year prior, while also announcing the expansion of its ALTO-207 program with plans for an additional Phase 3 trial in treatment-resistant depression. The company secured …

Is Coeur Mining (CDE) Undervalued After Record Gold Production And Strong Q2 Results?

Coeur Mining (CDE) is being re-evaluated after reporting record second-quarter gold production, significantly increased sales and net income, and updated full-year production guidance. While the stock has seen mixed short-term performance, its long-term returns have been robust, suggesting an ongoing recovery. Despite these positive …

Assenagon Asset Management S.A. Sells 707,062 Shares of Coeur Mining, Inc. $CDE

Projeções de Resultados: Euronet Worldwide Inc (EEFT) — LPA e Crescimento de Receita

Alto Neuroscience (ANRO) Earnings Date and Reports 2026

Neuronetics (STIM) Stock Repriced After Margin Gains And EBITDA Breakeven